UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA
Clinical trials for UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy trial aims to control Tough-to-Treat cancer
Disease control OngoingThis study is for adults with advanced dedifferentiated liposarcoma, a rare and aggressive cancer. It compares a standard cancer drug (palbociclib) alone versus the same drug combined with an immunotherapy drug (cemiplimab). The goal is to see if the two-drug combination is more …
Matched conditions: UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope for Tough-to-Treat liposarcoma: Dual-Action drug trial
Disease control OngoingThis study is testing whether a combination of two immunotherapy drugs, etrumadenant and zimberelimab, can help control advanced dedifferentiated liposarcoma. It is for adults whose cancer has spread, returned after prior treatment, or cannot be removed by surgery. The main goal …
Matched conditions: UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC